June 21, 2019
The Japan unit of Sanofi said on June 20 that iGlarLixi, an investigational fixed-dose combination drug pairing Lantus (insulin glargine) and Lyxumia (lixisenatide), demonstrated efficacy in a PIII study covering Japanese type 2 diabetes patients inadequately controlled with basal insulin...read more